{"id":3622,"date":"2026-10-03T08:03:26","date_gmt":"2026-10-03T06:03:26","guid":{"rendered":"https:\/\/energianucleare.eu\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\/"},"modified":"2026-10-03T08:03:26","modified_gmt":"2026-10-03T06:03:26","slug":"orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies","status":"publish","type":"post","link":"https:\/\/energianucleare.eu\/en\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\/","title":{"rendered":"Orano Med opens ATLab Valenciennes, Europe&#8217;s first industrial facility for lead-212 targeted alpha therapies"},"content":{"rendered":"<p><strong>Orano Med<\/strong> has officially opened <strong>ATLab Valenciennes<\/strong>, Europe&#8217;s first industrial facility entirely dedicated to the production of <strong>lead-212<\/strong>-based targeted alpha therapies (TAT). Located in Onnaing, northern France, the site marks a decisive step from experimental research to large-scale manufacturing of one of the most anticipated drug classes in oncology today.<\/p>\n<p>The inauguration ceremony was attended by Claude Imauven, Chairman of Orano&#8217;s Board of Directors, and Nicolas Maes, CEO of the group. At interim capacity, ATLab Valenciennes will be able to produce up to 10,000 doses per year, with the potential to scale up fivefold at full operation. The facility covers more than 3,000 square metres, represents a \u20ac29 million investment, and is expected to create around 25 direct jobs. The project was selected under the France 2030 plan and received nearly \u20ac3.8 million in public funding.<\/p>\n<p>Lead-212 targeted alpha therapies work on a precise principle: lead-212 combines the natural ability of biological molecules to home in on cancer cells with the high-energy properties of alpha emissions, which act within an extremely limited range. The result is highly targeted tumour destruction with minimal damage to surrounding healthy tissue. Until now, the development of these therapies had been held back by the absence of facilities capable of producing them at industrial scale. ATLab Valenciennes removes that barrier for the European market.<\/p>\n<p>The two ATLab facilities together form Orano Med&#8217;s integrated global industrial platform. Underpinned by a proprietary chemical process for lead-212 production and secured access to raw materials, Orano Med is well positioned to tackle the key challenges in TAT manufacturing \u2014 including isotope availability and production scalability. The short half-life of lead-212 \u2014 just 10.6 hours \u2014 means these drugs must be produced close to the hospitals where they will be used. The plant&#8217;s location in the heart of the Valenciennes metropolitan area, with fast access to Brussels and Paris-Roissy airports, directly addresses this logistical constraint.<\/p>\n<p>The Brownsburg ATLab, near Indianapolis, was already inaugurated in June 2024 and serves the North American market. Valenciennes completes the picture: two production hubs, two continents, one shared platform. The project also fits within France&#8217;s broader acceleration strategy for biology and bioproduction, with a specific focus on developing new oncology therapies. The public funding secured is no minor footnote \u2014 it signals that both France and the European Union view nuclear medicine as a strategic sector worthy of targeted investment.<\/p>\n<p>With ATLab Valenciennes now operational, <strong>Orano Med<\/strong> has the industrial infrastructure to move drug candidates still in clinical trials toward continent-wide availability. Further ATLab facilities are already planned to meet patient needs globally. Lead-212 could become one of the most significant isotopes in oncology over the next decade \u2014 and the race to build production capacity has only just begun.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Orano Med has inaugurated ATLab Valenciennes in Onnaing, France \u2014 Europe&#8217;s first industrial-scale facility dedicated to producing lead-212 targeted alpha therapies, with a capacity of 10,000 doses per year. The \u20ac29 million investment, backed by the France 2030 plan, completes Orano&#8217;s global industrial platform alongside its ATLab in Indianapolis.<\/p>\n","protected":false},"author":25,"featured_media":3619,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[],"tags":[],"class_list":["post-3622","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Orano Med opens ATLab Valenciennes, Europe&#039;s first industrial facility for lead-212 targeted alpha therapies - Energia nucleare<\/title>\n<meta name=\"description\" content=\"Orano Med opens ATLab Valenciennes, Europe&#039;s first industrial plant for lead-212 targeted alpha therapies: \u20ac29M investment, 10,000 doses\/year.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/energianucleare.eu\/en\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Orano Med opens ATLab Valenciennes, Europe&#039;s first industrial facility for lead-212 targeted alpha therapies - Energia nucleare\" \/>\n<meta property=\"og:description\" content=\"Orano Med opens ATLab Valenciennes, Europe&#039;s first industrial plant for lead-212 targeted alpha therapies: \u20ac29M investment, 10,000 doses\/year.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/energianucleare.eu\/en\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\/\" \/>\n<meta property=\"og:site_name\" content=\"Energia nucleare\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-03T06:03:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/energianucleare.eu\/wp-content\/uploads\/2026\/10\/publish_e4a3d32909944ec4a5d72667d37efaf8.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1536\" \/>\n\t<meta property=\"og:image:height\" content=\"1024\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Redazione Energia Nucleare\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Redazione Energia Nucleare\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/energianucleare.eu\\\/en\\\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/energianucleare.eu\\\/en\\\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\\\/\"},\"author\":{\"name\":\"Redazione Energia Nucleare\",\"@id\":\"https:\\\/\\\/energianucleare.eu\\\/en\\\/#\\\/schema\\\/person\\\/2c3f466ad139658dfa60c575cf287fb7\"},\"headline\":\"Orano Med opens ATLab Valenciennes, Europe&#8217;s first industrial facility for lead-212 targeted alpha therapies\",\"datePublished\":\"2026-10-03T06:03:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/energianucleare.eu\\\/en\\\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\\\/\"},\"wordCount\":463,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/energianucleare.eu\\\/en\\\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/energianucleare.eu\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/publish_e4a3d32909944ec4a5d72667d37efaf8.jpg\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/energianucleare.eu\\\/en\\\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/energianucleare.eu\\\/en\\\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\\\/\",\"url\":\"https:\\\/\\\/energianucleare.eu\\\/en\\\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\\\/\",\"name\":\"Orano Med opens ATLab Valenciennes, Europe's first industrial facility for lead-212 targeted alpha therapies - Energia nucleare\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/energianucleare.eu\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/energianucleare.eu\\\/en\\\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/energianucleare.eu\\\/en\\\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/energianucleare.eu\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/publish_e4a3d32909944ec4a5d72667d37efaf8.jpg\",\"datePublished\":\"2026-10-03T06:03:26+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/energianucleare.eu\\\/en\\\/#\\\/schema\\\/person\\\/2c3f466ad139658dfa60c575cf287fb7\"},\"description\":\"Orano Med opens ATLab Valenciennes, Europe's first industrial plant for lead-212 targeted alpha therapies: \u20ac29M investment, 10,000 doses\\\/year.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/energianucleare.eu\\\/en\\\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/energianucleare.eu\\\/en\\\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/energianucleare.eu\\\/en\\\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\\\/#primaryimage\",\"url\":\"https:\\\/\\\/energianucleare.eu\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/publish_e4a3d32909944ec4a5d72667d37efaf8.jpg\",\"contentUrl\":\"https:\\\/\\\/energianucleare.eu\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/publish_e4a3d32909944ec4a5d72667d37efaf8.jpg\",\"width\":1536,\"height\":1024},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/energianucleare.eu\\\/en\\\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/energianucleare.eu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Orano Med opens ATLab Valenciennes, Europe&#8217;s first industrial facility for lead-212 targeted alpha therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/energianucleare.eu\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/energianucleare.eu\\\/en\\\/\",\"name\":\"Energia nucleare\",\"description\":\"Notizie sul nucleare\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/energianucleare.eu\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/energianucleare.eu\\\/en\\\/#\\\/schema\\\/person\\\/2c3f466ad139658dfa60c575cf287fb7\",\"name\":\"Redazione Energia Nucleare\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f7573bf636adfceb968c63d469c0889af0a78eb4935f321c17f76df121e056a6?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f7573bf636adfceb968c63d469c0889af0a78eb4935f321c17f76df121e056a6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f7573bf636adfceb968c63d469c0889af0a78eb4935f321c17f76df121e056a6?s=96&d=mm&r=g\",\"caption\":\"Redazione Energia Nucleare\"},\"url\":\"https:\\\/\\\/energianucleare.eu\\\/en\\\/author\\\/redazione\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Orano Med opens ATLab Valenciennes, Europe's first industrial facility for lead-212 targeted alpha therapies - Energia nucleare","description":"Orano Med opens ATLab Valenciennes, Europe's first industrial plant for lead-212 targeted alpha therapies: \u20ac29M investment, 10,000 doses\/year.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/energianucleare.eu\/en\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\/","og_locale":"en_US","og_type":"article","og_title":"Orano Med opens ATLab Valenciennes, Europe's first industrial facility for lead-212 targeted alpha therapies - Energia nucleare","og_description":"Orano Med opens ATLab Valenciennes, Europe's first industrial plant for lead-212 targeted alpha therapies: \u20ac29M investment, 10,000 doses\/year.","og_url":"https:\/\/energianucleare.eu\/en\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\/","og_site_name":"Energia nucleare","article_published_time":"2026-10-03T06:03:26+00:00","og_image":[{"width":1536,"height":1024,"url":"https:\/\/energianucleare.eu\/wp-content\/uploads\/2026\/10\/publish_e4a3d32909944ec4a5d72667d37efaf8.jpg","type":"image\/jpeg"}],"author":"Redazione Energia Nucleare","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Redazione Energia Nucleare","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/energianucleare.eu\/en\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\/#article","isPartOf":{"@id":"https:\/\/energianucleare.eu\/en\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\/"},"author":{"name":"Redazione Energia Nucleare","@id":"https:\/\/energianucleare.eu\/en\/#\/schema\/person\/2c3f466ad139658dfa60c575cf287fb7"},"headline":"Orano Med opens ATLab Valenciennes, Europe&#8217;s first industrial facility for lead-212 targeted alpha therapies","datePublished":"2026-10-03T06:03:26+00:00","mainEntityOfPage":{"@id":"https:\/\/energianucleare.eu\/en\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\/"},"wordCount":463,"commentCount":0,"image":{"@id":"https:\/\/energianucleare.eu\/en\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/energianucleare.eu\/wp-content\/uploads\/2026\/10\/publish_e4a3d32909944ec4a5d72667d37efaf8.jpg","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/energianucleare.eu\/en\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/energianucleare.eu\/en\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\/","url":"https:\/\/energianucleare.eu\/en\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\/","name":"Orano Med opens ATLab Valenciennes, Europe's first industrial facility for lead-212 targeted alpha therapies - Energia nucleare","isPartOf":{"@id":"https:\/\/energianucleare.eu\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/energianucleare.eu\/en\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\/#primaryimage"},"image":{"@id":"https:\/\/energianucleare.eu\/en\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\/#primaryimage"},"thumbnailUrl":"https:\/\/energianucleare.eu\/wp-content\/uploads\/2026\/10\/publish_e4a3d32909944ec4a5d72667d37efaf8.jpg","datePublished":"2026-10-03T06:03:26+00:00","author":{"@id":"https:\/\/energianucleare.eu\/en\/#\/schema\/person\/2c3f466ad139658dfa60c575cf287fb7"},"description":"Orano Med opens ATLab Valenciennes, Europe's first industrial plant for lead-212 targeted alpha therapies: \u20ac29M investment, 10,000 doses\/year.","breadcrumb":{"@id":"https:\/\/energianucleare.eu\/en\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/energianucleare.eu\/en\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/energianucleare.eu\/en\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\/#primaryimage","url":"https:\/\/energianucleare.eu\/wp-content\/uploads\/2026\/10\/publish_e4a3d32909944ec4a5d72667d37efaf8.jpg","contentUrl":"https:\/\/energianucleare.eu\/wp-content\/uploads\/2026\/10\/publish_e4a3d32909944ec4a5d72667d37efaf8.jpg","width":1536,"height":1024},{"@type":"BreadcrumbList","@id":"https:\/\/energianucleare.eu\/en\/orano-med-opens-atlab-valenciennes-europes-first-industrial-facility-for-lead-212-targeted-alpha-therapies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/energianucleare.eu\/en\/"},{"@type":"ListItem","position":2,"name":"Orano Med opens ATLab Valenciennes, Europe&#8217;s first industrial facility for lead-212 targeted alpha therapies"}]},{"@type":"WebSite","@id":"https:\/\/energianucleare.eu\/en\/#website","url":"https:\/\/energianucleare.eu\/en\/","name":"Energia nucleare","description":"Notizie sul nucleare","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/energianucleare.eu\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/energianucleare.eu\/en\/#\/schema\/person\/2c3f466ad139658dfa60c575cf287fb7","name":"Redazione Energia Nucleare","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/f7573bf636adfceb968c63d469c0889af0a78eb4935f321c17f76df121e056a6?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f7573bf636adfceb968c63d469c0889af0a78eb4935f321c17f76df121e056a6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f7573bf636adfceb968c63d469c0889af0a78eb4935f321c17f76df121e056a6?s=96&d=mm&r=g","caption":"Redazione Energia Nucleare"},"url":"https:\/\/energianucleare.eu\/en\/author\/redazione\/"}]}},"_links":{"self":[{"href":"https:\/\/energianucleare.eu\/en\/wp-json\/wp\/v2\/posts\/3622","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/energianucleare.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/energianucleare.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/energianucleare.eu\/en\/wp-json\/wp\/v2\/users\/25"}],"replies":[{"embeddable":true,"href":"https:\/\/energianucleare.eu\/en\/wp-json\/wp\/v2\/comments?post=3622"}],"version-history":[{"count":0,"href":"https:\/\/energianucleare.eu\/en\/wp-json\/wp\/v2\/posts\/3622\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/energianucleare.eu\/en\/wp-json\/wp\/v2\/media\/3619"}],"wp:attachment":[{"href":"https:\/\/energianucleare.eu\/en\/wp-json\/wp\/v2\/media?parent=3622"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/energianucleare.eu\/en\/wp-json\/wp\/v2\/categories?post=3622"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/energianucleare.eu\/en\/wp-json\/wp\/v2\/tags?post=3622"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}